JP5885085B2 - システアミン誘導体、および非アルコール性脂肪性肝炎の治療におけるその使用 - Google Patents
システアミン誘導体、および非アルコール性脂肪性肝炎の治療におけるその使用 Download PDFInfo
- Publication number
- JP5885085B2 JP5885085B2 JP2013513777A JP2013513777A JP5885085B2 JP 5885085 B2 JP5885085 B2 JP 5885085B2 JP 2013513777 A JP2013513777 A JP 2013513777A JP 2013513777 A JP2013513777 A JP 2013513777A JP 5885085 B2 JP5885085 B2 JP 5885085B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction mixture
- solution
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Description
本出願は2010年6月8日に提出されたアメリカ合衆国仮特許出願番号61/352438の優先権を主張するものである。本出願はここに参照によりそのすべての開示内容に関して全体を組み込むものである。
(I)
(I)
R2はまた、独立して、水素、カルボキシル、アミン、−NH−CO−NH−、−NH−CO−CH2−NH−、−NH−CO−、R−COO−R1、チオール、ジスルフィドの少なくとも1つを表す
R3は、独立して、以下の少なくとも1つを表す。
(I)
R2はまた、独立して、水素、カルボキシル、アミン、−NH−CO−NH−、−NH−CO−CH2−NH−、−NH−CO−、R−COO−R1、チオール、ジスルフィドの少なくとも1つを表す。
R3は、独立して、以下の少なくとも1つを表す。
たとえば、
(Ia)
(Ib)
(I)
R2はまた、独立して、水素、カルボキシル、アミン、−NH−CO−NH−、−NH−CO−CH2−NH−、−NH−CO−、R−COO−R1、チオール、ジスルフィドの少なくとも1つを表す。
R3は、独立して、下記の少なくとも1つを表す。
例えば、
(Ia) (Ib)
(I)
の少なくとも1つを表し、R3は、独立して、下記の少なくとも1つを表す。
例えば、
(Ia)
(Ib)
(Ic)
(Id)
最終化合物
この発明にかなう適切な単位投与形態としては、錠剤、カプセル剤、トローチ剤、坐剤、粉末パケット、ウエハース、カシェ剤、茶さじ分、大匙分、スポイト分、アンプル、バイアル、また上記のいずれかの隔離された倍数、および本明細書に既述された他の形態である。
調節された放出の種類には、制御、長時間化、持続、拡張、遅延、拍動性、反復行動化されたなどが挙げられる。これらの種類の調節された放出を達成するための適切なメカニズムには、拡散、浸食、ジオメトリおよび/または不浸透性の障壁を介した表面面積制御、または当技術分野で公知の他のメカニズムを含む。
合成の方法:
(I)
R2はまた、独立して、水素、カルボキシル、アミン、−NH−CO−NH−、−NH−CO−CH2−NH−、−NH−CO−、R−COO−R1、チオール、ジスルフィド
の少なくとも1つを表す。R3はまた、独立して
の少なくとも1つを表す。
Claims (8)
- 下記化学式で表される化合物。
- 式Iの化合物は代謝性疾患の治療のために処方される、請求項1に記載の化合物。
- 式Iの化合物は神経変性疾患の治療のために処方される、請求項1に記載の化合物。
- 式Iの化合物は、非経口投与、注射、皮下、経口液剤、経口投与及び経皮投与の少なくとも一つのために処方される、請求項1に記載の化合物。
- 経口投与は遅延放出または徐放性製剤の少なくとも一つを含む腸溶性コーティングを有する、請求項4に記載の化合物。
- 請求項1に記載の化合物の合成法であって、
水素化アルミニウムリチウムを0℃で、THF中のエイコサペンタエン酸の懸濁液としてTHF溶液中で混合する工程と、
反応混合物を室温に温める工程と、
一晩室温を維持する工程と、
前記反応混合物を飽和硫酸ナトリウムで急冷し、酢酸エチルで抽出する工程と、
有機層を分離し、ブラインで洗浄する工程と、
洗浄された層を無水Na2SO4で乾燥し、第一の化合物を作るために、減圧下で蒸発させる工程と、
カラムクロマトグラフィーにより第一の化合物を精製する工程と、
室温でアルコール及びピリジンのDCM溶液に4−ニトロフェニルクロロホルメートを混合する工程と、
第一の化合物と溶液を室温で3時間撹拌する工程と、
薄層クロマトグラフィーにより反応の終了を監視する工程と、
反応混合物をDCMで希釈する工程と、
水で洗浄し、続いてNaHCO3溶液で洗浄する工程と、
無水Na 2 SO 4 で反応混合物を乾燥し、減圧下で蒸発させて固体を形成する工程と、
酢酸エチル8%で固形物を精製および溶出し、溶離剤として第二の化合物を無色の液体として得る工程と、
溶離液として8パーセント酢酸エチル−ペットのエーテルを使用して100〜200メッシュのシリカゲルのカラムクロマトグラフィーで溶離液の第二の化合物を精製する工程と、
2−アミノエタンチオール塩酸のTFA溶液にトリチルアルコールを0℃で添加する工程と、
室温で3時間反応混合物を撹拌する工程と、
反応混合物を、飽和NaHCO3溶液で急冷し、EtOACで抽出する工程と、
水(2×100mL)で洗浄し、次にブライン溶液で洗浄する工程と、
無水Na 2 SO 4 上で乾燥させ、減圧下で蒸発させて粘稠な油としての粗生成物を得る工程と、
シリカゲル60〜120メッシュと、溶離液としてクロロホルム中の5%MeOH上で、カラムクロマトグラフィーを用いて精製し、溶出し、第三の化合物をトリチル保護された白色固体として得る工程と、
室温で乾燥DMF中の第二の化合物の溶液に第三の化合物を加える工程と、
室温で2時間、反応混合物を保持する工程と、
減圧下で反応混合物を蒸発させる工程と、
この反応混合物を60〜120メッシュのシリカゲル上でカラムクロマトグラフィー使用し、14%酢酸エチル−ペットのエーテルを加えて精製、溶出し、第四の化合物を無色液体として得る工程と、
第四の化合物の20%TFA/DCM溶液とトリエチルシランを0℃で滴下により添加する工程と、
0℃で30分間反応混合物を撹拌する工程と、
薄層クロマトグラフィーを用いて反応の終了を監視する工程と、
この反応混合物と飽和NaHCO3溶液を混合し、DCMで抽出する工程と、
前記反応混合物を一緒にした有機層をブライン溶液で洗浄する工程と、
無水Na 2 SO 4 上で反応混合物を乾燥させ、減圧下で蒸発させる工程と、
溶離剤として酢酸エチル−ペットエチルエーテル15%を使用し、60〜120メッシュのシリカゲル上でカラムクロマトグラフィーを用いて精製し、請求項1に記載の化合物Iを無色の液体として得る工程。 - 下記化学式で示される化合物と薬学的に許容されるその塩を含む、キット。
- 神経変性障害および代謝性疾患の少なくとも1つを治療するにあたり使用する指示をさらに含む、請求項7記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35243810P | 2010-06-08 | 2010-06-08 | |
US61/352,438 | 2010-06-08 | ||
PCT/IB2011/001550 WO2011154833A1 (en) | 2010-06-08 | 2011-06-03 | Cysteamine derivatives and their use in the treatment of nash |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013529221A JP2013529221A (ja) | 2013-07-18 |
JP5885085B2 true JP5885085B2 (ja) | 2016-03-15 |
Family
ID=44532960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013513777A Active JP5885085B2 (ja) | 2010-06-08 | 2011-06-03 | システアミン誘導体、および非アルコール性脂肪性肝炎の治療におけるその使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110300190A1 (ja) |
EP (1) | EP2580204B1 (ja) |
JP (1) | JP5885085B2 (ja) |
CN (1) | CN102947287A (ja) |
AU (1) | AU2011263423B2 (ja) |
BR (1) | BR112012031194A2 (ja) |
CA (1) | CA2801336C (ja) |
IL (1) | IL223241A (ja) |
SG (1) | SG185754A1 (ja) |
WO (1) | WO2011154833A1 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014045293A1 (en) * | 2012-09-24 | 2014-03-27 | Krisani Bioscience (P) Ltd. | Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof |
CA2847418A1 (en) * | 2011-08-31 | 2013-03-07 | Jill C. Milne | Fatty acid amides useful in the treatment of inflammatory disorders |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
EP2847169A4 (en) | 2012-05-07 | 2015-09-30 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
SG11201407319YA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
JP2015518855A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 粘膜炎の治療のための組成物および方法 |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
JP2015529218A (ja) | 2012-09-08 | 2015-10-05 | セリックスビオ プライヴェート リミテッド | 炎症と脂質障害の治療のための組成物及び方法 |
US20150126568A1 (en) * | 2012-09-13 | 2015-05-07 | Mahesh Kandula | Compositions and methods for the treatment of hypertension and management of diabetic kidney disease |
WO2014057407A2 (en) * | 2012-10-12 | 2014-04-17 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and prediabetes |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
DK3242869T3 (da) | 2015-01-06 | 2022-01-31 | Cellix Bio Private Ltd | Sammensætninger og fremgangsmåder til behanding af inflammation og smerte |
US11173135B2 (en) | 2016-03-17 | 2021-11-16 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
WO2018174838A1 (en) * | 2017-03-18 | 2018-09-27 | Nguyen Mark Quang | Cysteamine prodrugs, related analogs, pharmaceutical compositions thereof, and methods of use |
JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス, インコーポレイテッド | システアミン感受性障害の治療方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5681578A (en) * | 1979-12-07 | 1981-07-03 | Shionogi & Co Ltd | Novel thioalkyl amide derivative |
JPS6257A (ja) * | 1985-03-19 | 1987-01-06 | Green Cross Corp:The | 含硫アミン−脂肪酸のアミド誘導体 |
JPH07505283A (ja) * | 1992-03-20 | 1995-06-15 | ベイラー・カレッジ・オブ・メディシン | Dnaトランスポーター系および使用方法 |
CA2192965C (en) * | 1994-07-11 | 2007-12-04 | David W. Pate | Anandamide analogue compositions and method of treating intraocular hypertension using same |
US6699851B2 (en) * | 2000-07-12 | 2004-03-02 | Ardenia Investments, Ltd. | Cytotoxic compounds and their use |
CN101535238A (zh) * | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
WO2009028457A1 (ja) * | 2007-08-29 | 2009-03-05 | Shinshu University | 非アルコール性脂肪肝炎治療薬 |
MX2010005921A (es) * | 2007-11-30 | 2010-06-11 | Univ California | Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina. |
WO2011044139A1 (en) * | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid acifran derivatives and their uses |
-
2011
- 2011-06-03 CN CN2011800285640A patent/CN102947287A/zh active Pending
- 2011-06-03 WO PCT/IB2011/001550 patent/WO2011154833A1/en active Application Filing
- 2011-06-03 EP EP11749511.9A patent/EP2580204B1/en active Active
- 2011-06-03 US US13/152,864 patent/US20110300190A1/en not_active Abandoned
- 2011-06-03 BR BR112012031194A patent/BR112012031194A2/pt not_active Application Discontinuation
- 2011-06-03 SG SG2012086765A patent/SG185754A1/en unknown
- 2011-06-03 AU AU2011263423A patent/AU2011263423B2/en active Active
- 2011-06-03 CA CA2801336A patent/CA2801336C/en active Active
- 2011-06-03 JP JP2013513777A patent/JP5885085B2/ja active Active
-
2012
- 2012-11-25 IL IL223241A patent/IL223241A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2801336C (en) | 2020-01-28 |
CA2801336A1 (en) | 2011-12-15 |
US20110300190A1 (en) | 2011-12-08 |
AU2011263423B2 (en) | 2016-10-20 |
IL223241A (en) | 2017-12-31 |
AU2011263423A1 (en) | 2012-08-23 |
WO2011154833A1 (en) | 2011-12-15 |
SG185754A1 (en) | 2012-12-28 |
IL223241A0 (en) | 2013-02-03 |
CN102947287A (zh) | 2013-02-27 |
BR112012031194A2 (pt) | 2018-05-29 |
EP2580204B1 (en) | 2017-03-08 |
JP2013529221A (ja) | 2013-07-18 |
EP2580204A1 (en) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5885085B2 (ja) | システアミン誘導体、および非アルコール性脂肪性肝炎の治療におけるその使用 | |
WO2013017974A1 (en) | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases | |
WO2013008182A1 (en) | Prodrugs of gaba analogs | |
KR102357471B1 (ko) | 중수소 농축 N-아세틸시스테인 아미드(D-NACA) 및 (2R,2R')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(Di-NACA)의 제조방법 및 산화 스트레스를 포함하는 질환을 치료하기 위한 D-NACA 및 Di-NACA의 사용방법 | |
WO2013024376A1 (en) | Compositions and methods for the treatment of atherothrombosis | |
WO2014141057A2 (en) | Compositions and methods for the treatment of cancer | |
US9642915B2 (en) | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases | |
US8871805B2 (en) | Compound, composition and uses thereof | |
WO2016046675A1 (en) | Compositions and methods for the treatment of neurological diseases | |
WO2017090007A1 (en) | Compositions and methods for the treatment of urea cycle disorders and hepatic diseases | |
US9475747B1 (en) | Compositions and methods for the treatment of urea cycle disorders and gout | |
WO2016046674A1 (en) | Compositions and methods for the treatment of moderate to severe pain | |
JP5874128B2 (ja) | 化合物、組成物、製剤、およびそれらの使用 | |
WO2013014565A1 (en) | Compositions and methods for the treatment of metabolic conditions and muscular disorders | |
WO2013017977A1 (en) | Compositions and methods for the treatment of cancer | |
WO2017060914A2 (en) | Penicillamine and its derivatives are used in the treatment of copper toxicity and nash | |
CA2976314C (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
CA2965449C (en) | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis | |
WO2016132186A1 (en) | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome | |
WO2013030692A1 (en) | Compositions and methods for the treatment of chronic pain | |
WO2017037566A1 (en) | Compound, composition and uses thereof | |
WO2017221083A1 (en) | Compositions and methods for the treatment of viral infections | |
AU2015356569A1 (en) | Compositions and methods for the treatment of multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140602 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20150608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151116 |
|
TRDD | Decision of grant or rejection written | ||
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151218 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5885085 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |